iRhythm vs NovoCure
IRTC and NVCR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRTC and NVCR compare
iRhythm is the larger company, worth 2.3 times as much as NovoCure ($3.0B against $1.3B).
iRhythm grew revenue faster over the last twelve months (25.6% versus 12.9% for NovoCure).
iRhythm keeps more of each dollar of sales as profit, with a net margin of −1.7% compared with −16.8% at NovoCure.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRTC | NVCR |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | $1.3B |
| Share price | $89.67 | $11.14 |
| Change, 1 year | −47.5% | −1.6% |
| Change, 5 years | −8.5% | −88.5% |
| Beta (5Y) | 1.39 | 1.23 |
| Employees | 2,400 | 1,605 |
| StockData Score | ||
| Total score | 9 | 9 |
| Valuation score | 1 | 2 (better) |
| Growth score | 4 (better) | 3 |
| Performance score | 3 (better) | 1 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× | 1.8× (better) |
| P/B | 15.9× | 3.7× (better) |
| P/FCF | 75.8× | – |
| FCF yield | 1.3% (better) | −1.9% |
| Fair value | $92.19 | $16.21 |
| Margin of safety | 2.7% | 31.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 25.6% (better) | 12.9% |
| Revenue growth, 5Y average | 23.0% (better) | 5.8% |
| Profitability | ||
| Gross margin | 71.5% | 77.0% (better) |
| Operating margin | −3.0% (better) | −17.2% |
| Net margin | −1.7% (better) | −16.8% |
| FCF margin | 4.7% (better) | −3.4% |
| Return on equity | −9.6% (better) | −35.2% |
| Return on invested capital | – | −70.8% |
| Financial health | ||
| Debt / equity | – | 0.07 |
| Interest coverage | −1.9× | – |
| Current ratio | 3.85 (better) | 2.49 |
| Altman Z-score | 2.20 (better) | 0.25 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.28% |
| Shareholder yield | 0.00% (better) | −0.28% |
| Ownership | ||
| Held by institutions | 108% | 88.5% |
| Held by insiders | 2.1% | 3.0% |
| Insider net buying, 12 months | −$24.4M | −$3.4M (better) |
| Short interest, % of float | 10.1% | 11.4% |
Go deeper
- IRTC stock overview
- IRTC income statement
- IRTC valuation and score
- NVCR stock overview
- NVCR income statement
- NVCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.